P
CRBU icon

&Partners’s Caribou Biosciences CRBU Stock Holding History

&Partners’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$61.8K Sell
32,505
-3,000
-8% -$5.15K ﹤0.01% 2362
2025
Q4 		$56.5K Sell
35,505
-8,634
-20% -$18.1K ﹤0.01% 2239
2025
Q3 		$103K Sell
44,139
-292,426
-87% -$552K ﹤0.01% 2051
2025
Q2 		$424K Buy
+336,565
New +$331K ﹤0.01% 1431

Other funds holding CRBU

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

&Partners's CRBU Position: Q1 2026 in Review

&Partners reduced its Caribou Biosciences (CRBU) stake by 8.4% in Q1 2026, selling an estimated $5.15K and leaving 32,505 shares worth $61.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2362.

&Partners first reported a position in CRBU in Q2 2025 and has held it in 4 quarters since. The position peaked at $424K in Q2 2025. 137 funds tracked by Wall St. Rank hold CRBU as of Q1 2026.

  • &Partners held 32,505 shares of Caribou Biosciences worth $61.8K as of Q1 2026.
  • &Partners sold 3,000 Caribou Biosciences shares in Q1 2026, an estimated $5.15K.
  • Caribou Biosciences made up ﹤0.01% of &Partners's portfolio in Q1 2026, its #2362 holding.
  • &Partners first reported a position in Caribou Biosciences in Q2 2025 and has held it in 4 quarters since.
  • &Partners's Caribou Biosciences position peaked at $424K in Q2 2025.
  • 137 funds tracked by Wall St. Rank held Caribou Biosciences as of Q1 2026.

Based on &Partners's 13F filing for Q1 2026, filed 15 May 2026.